Gastroprotective Activity of FRG-8813, a Novel Histamine H2-Receptor Antagonist, in Rats
Authors:
- Masahiro ShibataMSMasahiro Shibata
- Masato TanakaMTMasato Tanaka
- Niro InabaNINiro Inaba
- Tetsuaki YamauraTYTetsuaki Yamaura
- Haruo OhnishiHOHaruo Ohnishi
Open Access
- 1 January 1995
- journal article
- Published by Elsevier in The Japanese Journal of Pharmacology
- Vol. 68 (2) , 161-173
Abstract
FRG-8813 ((+/-)-2-(furfurylsulfinyl)-N-[4-[4-(piperidinomethyl)-2- pyridyl]oxy-(Z)-2-butenyl]acetamide) is a novel histamine H2-receptor antagonist with gastric antisecretory and gastroprotective activities. The present study was designed to investigate the property of gastroprotective action. The oral ED50 values for inhibition of mucosal lesions against 1% NH3-, 60% ethanol in 0.15 N HCl-, 100% ethanol-, 0.6 N HCl- and sodium taurocholate in 0.4 N HCl-induced damage were 3.3, 11.1, 14.9, 23.3 and 23.1 mg/kg, respectively. FRG-8813 was gastroprotective despite pretreatment with omeprazole, suggesting that the protective effect is independent of its antisecretory activity. It is unlikely that FRG-8813 works as a mild irritant because it showed a gastroprotective effect after intraperitoneal injection, but oral administration itself did not influence the rat gastric mucosa. Although pretreatment with indomethacin or N-ethylmaleimide did not affect the gastroprotection of FRG-8813, chemical deafferentation induced by capsaicin abolished the gastroprotection. Furthermore, prior administration of tetrodotoxin, the calcitonin gene-related peptide (CGRP) antagonist hCGRP or NG-nitro-L-arginine attenuated the gastroprotection of FRG-8813 as well as that of capsaicin. In contrast to capsaicin, repeated administration of FRG-8813 neither enhanced the susceptibility of the mucosa to damage nor affected the gastroprotective action of short-term treatment. In conclusion, these results suggest that FRG-8813 has gastroprotective activity independently of acid antisecretory activity and that capsaicin-sensitive nerves may be partially or fully involved in the gastroprotective mechanisms of FRG-8813.Keywords
This publication has 48 references indexed in Scilit:
- Gastric antisecretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogsEuropean Journal of Pharmacology, 1993
- Effects of FRG-8813, a new type histamine H2-receptor antagonist, on various experimental gastric and duodenal lesions in rats.Folia Pharmacologica Japonica, 1992
- Effects of FRG-8813, a new-type histamine H2-receptor antagonist, on the healing of gastric and duodenal ulcer in rats and spontaneously ulcerative mice.Folia Pharmacologica Japonica, 1992
- Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.Gut, 1987
- Cytoprotection by Prostaglandin Occurs in Spite of Penetration of Absolute Ethanol Into the Gastric MucosaGastroenterology, 1985
- The potentiation of taurocholate‐induced rat gastric erosions following parenteral administration of cyclo‐oxygenase inhibitorsBritish Journal of Pharmacology, 1983
- DIFFERENCE IN RELAPSE RATES OF DUODENAL ULCER AFTER HEALING WITH CIMETIDINE OR TRIPOTASSIUM DICITRATO BISMUTHATEThe Lancet, 1981
- Recurrence of duodenal ulcer pain after treatment with cimetidine for four and eight weeks.Gut, 1980
- Cytoprotection by prostaglandins in ratsGastroenterology, 1979
- Controlled trial of maintenance cimetidine treatment in healed duodenal ulcer: short and long-term effects.Gut, 1979